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ABSTRACT
Background: The characteristics of inpatients with severe asthma exacerbation remain unclear. It is consid-
ered that the characteristics of inpatients with severe asthma vary depending on age. However, these are
rarely investigated. The objective of this study is to investigate the differences in characteristics among different
age groups. We considered that it is necessary to understand the characteristics of each age group so that we
can establish strategies in preventing severe asthma exacerbation.
Methods: All asthma inpatients who were hospitalized between 2004 and 2011 with SpO2 <90% (in room air),
were breathless at rest, and showed increased respiratory rate and pulse rate were examined. We compared
the characteristics among the young age group, middle age group, and advanced age group.
Results: The total number of patients was 204. In the young age group, the percentages of patients with ir-
regular visits and non visits to a medical institution were high. This group showed high percentages of smokers
and pet owners. The percentage of continuous ICS users in this group was 25.9%. The middle age group had
high rates of aspirin-intolerant asthma. The percentage of continuous ICS users in this group was 60.2%. In the
advanced age group, the percentages of patients with hypertensionheart disease, diabetes mellitus, and
COPD were high. This group showed good treatment adherence. The percentage of continuous ICS users in
this group was 77.4%.
Conclusions: The characteristics of inpatients with severe asthma vary depending on age. We need to estab-
lish countermeasures for asthma exacerbation according to the characteristics of patients depending on age.
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INTRODUCTION
Inhaled corticosteroids (ICS) have become the main
drugs in the treatment of asthma, because asthma
has been recognized as a chronic inflammatory disor-
der of the airways. Following this recognition, various
asthma guidelines were formulated because a com-
prehensive treatment strategy was required, result-
ing in asthma control being improved significantly. It
was reported that ICS use could decrease the inci-
dence of asthma related death and the number of pa-
tients with asthma exacerbation.1-3 As a result of the
spread of the asthma guidelines and ICS use, it was
reported that the incidence of asthma related death
and the number of patients with asthma exacerbation
significantly decreased in the United States,4,5 Can-
ada,6 and the United Kingdom.7 It was reported that
there was a decrease in asthma mortality rate in 20
countries in the 5- to 34-year-old group.8 In a survey
conducted by the Ministry of Health, Labour and
Welfare, the numbers of asthma related deaths and
inpatients with asthma exacerbation were found to be
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decreasing in Japan. However, the rate of mortality
due to bronchial asthma still remains higher in Japan
than in European countries.9 In Japan, it was pointed
out that the rates of mild type and moderate type
asthma associated with death increased, and regard-
ing the circumstances surrounding asthma related
deaths, there were many cases of sudden deaths and
unstable sudden aggravations.10 Various factors con-
tribute to asthma related death and near fatal asthma.
Asthma-admission-related costs are higher than other
medical costs. It was considered that the prevention
of asthma related death and near fatal asthma would
result in a reduction in medical costs.11 Uncontrolled
asthma results in losses for patients, their families,
and our society. The precautions against asthma re-
lated death and near fatal asthma are very important
from various points of view. However, the characteris-
tics of inpatients with severe asthma exacerbation re-
main unclear. Furthermore, it is considered that the
characteristics of inpatients with severe asthma vary
depending on age. However, they are rarely investi-
gated. We examined the differences in the character-
istics of inpatients with severe asthma exacerbation
among different age groups. We considered that it is
necessary to understand the characteristics of each
age group so that we can establish strategies in pre-
venting severe asthma exacerbation.
METHODS
STUDY POPULATION
We evaluated all asthma inpatients who were hospi-
talized at Sagamihara National Hospital, one of the
core hospitals for allergic diseases located in central
Japan, between January 2004 and December 2011.
We conducted a complete survey by a retrospective
cohort study. The medical records of the patients
were reviewed by their allergists or pulmonologists.
Patients with severe asthma exacerbation were de-
fined as those who satisfied the objective findings
(SpO2 <90% in room air, breathlessness at rest, an in-
creased respiratory rate of 30 beatsmin and a pulse
rate >120min) in accordance with the severity classi-
fication of asthma exacerbation based on GINA
guidelines.12 The exclusion criteria included an ab-
normal shadow in chest X-ray films, a clear heart fail-
ure, severe COPD, bronchiectasis, old tuberculosis,
interstitial pneumonitis, and chronic eosinophilic
pneumonia. This study was approved by the local eth-
nics committee.
OUTCOME VARIABLES
The evaluated clinical backgrounds were as follows:
age, gender, type of asthma, smoking history, pet
ownership, history of childhood asthma, onset age,
complications, trigger of exacerbation, prehospital se-
verity, status of adherence to asthma treatment, and
prehospital treatments. Each item was evaluated on
the basis of answers given in a questionnaire and to
specific questions asked by the allergists or pul-
monologists. Atopic asthma was defined as positivity
for specific IgE antibodies to more than two common
environmental allergens (e.g. house dust, mites, envi-
ronmental fungi, pets). Patients not satisfying this
definition were considered non atopic. Prehospital se-
verity was classified on the basis of GINA guidelines,
subjective symptoms, and treatments within one
month prior to asthma exacerbation onset. The sever-
ity of asthma was classified into four categories,
namely, intermittent, mild persistent, moderate per-
sistent, and severe persistent, in accordance with the
classification of the control level based on GINA
guidelines. Regarding the status of adherence to
asthma treatment, no visit to a medical institution
means that the patient had not visited a medical insti-
tution for one year prior to admission, and irregular
visits to a medical institution means that the patient
had visited only at the time of asthma exacerbation in
the year prior to admission. The complications were
determined on the basis of responses to a question-
naire. The complications were defined as the diseases
that had been diagnosed by medical doctors and
treated in the present or the past. Patients were diag-
nosed as having aspirin-intolerant asthma (AIA) when
they developed severe symptoms following the chal-
lenge test or internal use of NSAID. In addition, we
investigated the age-specific (young age, middle age,
advanced age) background characteristics of inpa-
tients with severe asthma exacerbation. The specific
criterion for young adults was not available. Wijes-
inghe used the criterion of less than 35 years of age
in his study of asthma mortality rate in 20 countries.8
Therefore, we used the criterion of less than 35 years
old as the definition of young adult asthma.
STATISTICAL ANALYSES
Data are expressed as arithmetic mean and standard
deviation (SD). We used the Mann-Whitney U-test, χ2
test, and Kruskal-Wallis test to determine statistically
significant differences. Analyses were conducted with
SPSS 11.0 for Windows (SPSS Japan Inc.). p < 0.05
was considered statistically significant.
RESULTS
BACKGROUND CHARACTERISTICS OF ALL IN-
PATIENTS
The background characteristics of all inpatients with
severe asthma exacerbation are shown in Table 1.
The total number of patients with severe asthma ex-
acerbation was 204 (85 men and 119 women, mean
age of 50.1 years). Atopic-type asthma accounted for
64.2% of the patients, 39.7% were current smokers,
33.3% were pet owners, 38.2% had mild asthma before
hospitalization, 21.6% had moderate persistent
asthma, and 40.2% had severe persistent asthma. The
most frequent trigger of severe asthma exacerbation
was infection. The total percentage of patients with
Background of Severe Asthma Exacerbation
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Table　1　Background characteristics of all inpatients
2004-2011
Total number of severe asthma exacerbations 204
Gender (male, %) 41.7%
Age (years) 50.1 ± 19.1
Type of asthma (atopy, %) 64.2%
Smoking Current smoker (%) 39.7%
 Ex-smoker (%) 19.1%
History of childhood asthma (%) 28.9%
Onset of asthma (years) 31.1 ± 21.0
Pet ownership (%) 33.3%
dog 22.1%
cat 10.3%
rabbit 4.4%
Trigger of exacerbation (%)
infection 64.2%
heavy weather 13.7%
exhaustion or emotional stress 6.4%
NSAIDs 2.0%
others 2.0%
uncertainty 11.8%
Complications
hypertension/heart disorder 25.0%
allergic rhinitis 27.0%
atopic dermatitis 17.7%
sinusitis 18.1%
diabetes mellitus 7.8%
aspirin-intolerant asthma (AIA) 19.6%
obesity 13.7%
psychiatric disorder 9.8%
COPD 7.8%
Prehospital severity
severe persistent type 40.2%
moderate persistent type 21.6%
mild persistent type 20.1%
intermittent type 18.1%
Status of adherence to asthma treatment
regular visits to a medical institution 55.9%
irregular visits to a medical institution 27.5%
none 16.7%
Prehospital treatments (%)
oral corticosteroid 17.7%
ICS 54.9%
SABA monotherapy as needed 16.7%
no treatment 27.5%
Days of hospitalization (days) 15.8 ± 13.7
unscheduled visits or non visit was 44.2%. The total
percentage of patients without treatment and with
short-acting inhaled β2 agonist (SABA) monotherapy
as needed was 44.2%. Regular ICS users accounted
for 54.9%.
AGE-SPECIFIC BACKGROUND CHARACTERIS-
TICS
The age-specific background characteristics of inpa-
tients with severe asthma exacerbation are shown in
Table 2. In the young age group (15-34 years old; 20
men and 38 women; mean age, 27.2 years), 48.2% had
mild asthma before hospitalization. This group
showed poor treatment adherence (74.1% were pa-
tients with unscheduled visits and non visit, and 25.9%
were continuous ICS users) and high percentages of
smokers and pet owners.
In the middle age group (35-64 years old; 41 men
and 52 women; mean age, 52.1 years), 48.4% had se-
vere asthma before hospitalization. This group had
high percentages of patients with AIA. The percent-
age of continuous ICS users in this group was 60.2%.
In the advanced age group (more than 65 years
old; 24 men and 29 women; mean age, 75.9 years),
high percentages of patients with of hypertension
heart disease, diabetes mellitus, and COPD were ob-
served. This group showed good treatment adher-
ence (79.3% were patients with scheduled visits, and
77.4% were continuous ICS users).
DISCUSSION
The characteristics and risk factors in inpatients with
severe asthma vary depending on age. We investi-
gated the characteristics of patients with severe
asthma exacerbation in Japan, and compared the
characteristics among different age groups. The
young age group had significantly high percentages
of smokers and pet owners. Smoking and pet owner-
ship are important asthma exacerbation factors.13 All
pet owners in the young age group showed an IgE
antibody level of more than 0.35 IUml for each pet
allergen. Cat and dog allergens can be found in virtu-
ally all homes, but, not surprisingly, homes with pets
contain much higher levels of the allergens than
homes without pets. Allergic sensitization to furred
pet allergens is quite common, and in some popula-
tions, more than 60% of children with asthma are sen-
sitized to cat or dog allergens.14 In animal-allergen-
sensitized asthma patients, animal allergen exposure
is directly linked to poor asthma outcomes.15,16 Smok-
ing causes inflammation and airway remodeling,17
makes asthma more difficult to control18,19 resulting
in more frequent admissions,20 and causes a more
rapid decline in lung function.21,22 Asthma patients
who smoke are poorly responsive to ICS23,24 and oral
steroids.25,26 In the medical care of asthma, we con-
sidered that the avoidance of exacerbation factors,
such as smoking and pet ownership, is very impor-
tant. Furthermore, the young age group showed poor
treatment adherence and included a small number of
continuous ICS users. There were many patients
without treatment, and there were patients on SABA
monotherapy as needed. Some studies have sug-
gested that young patients are associated with nonad-
Sekiya K et al.
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Table　2　Age-specifi c background characteristics of inpatients
15-34
years old
35-64
years old
More than
65 years old
P-value
 (Kruskal-Wallis)
Total number of severe asthma exacerbations 58 93 53 —
Gender (male, %) 34.5% 44.1% 45.3% 0.4206
Age (years) 27.2 ± 4.9＊ 52.1 ± 9.0＊＊ 75.9 ± 6.1＊＊＊ <0.0001
Type of asthma (atopy, %) 82.8% 68.9%＊＊ 35.9%＊＊＊ <0.0001
Current smoker (%) 62.1% 43.1%＊＊ 9.4%＊＊＊ <0.0001
Onset of asthma (years) 10.8 ± 10.5＊ 32.8 ± 16.6＊＊ 50.4 ± 16.6＊＊＊ <0.0001
Pet ownership (%) 55.2% 37.6%＊＊ 3.8%＊＊＊ <0.0001
Complications
hypertension/heart disorder 0%＊ 29.0%＊＊ 52.8%＊＊＊ <0.0001
allergic rhinitis 53.5%＊ 15.1% 18.9%＊＊＊ <0.0001
atopic dermatitis 27.6% 20.4%＊＊ 1.9%＊＊＊ 0.0012
sinusitis 15.5% 18.3% 20.8% 0.7744
diabetes mellitus 0% 9.7%＊＊ 22.6%＊＊＊ 0.0005
aspirin-intolerant asthma (AIA) 3.5%＊ 29.0% 20.8% 0.0006
psychiatric disorder 5.2% 15.1% 7.6% 0.1141
COPD 0% 4.3%＊＊ 20.1%＊＊＊ 0.0001
Prehospital severity
Ratio of moderate/severe type (%) 51.7% 62.4% 71.7% 0.0963
severe persistent type 19.0% 48.4%＊＊ 49.1%＊＊＊ 0.0005
moderate persistent type 32.8%＊ 14.0% 22.6% 0.0240
mild persistent type 17.2% 20.4% 22.6% 0.7741
intermittent type 31.0% 17.2% 5.7%＊＊＊ 0.0024
Status of adherence to asthma treatment
Ratio of irregular visits to a medical institution/none (%) 74.1%＊ 38.7% 20.1%＊＊＊ <0.0001
regular visits to a medical institution 25.9%＊ 61.2% 79.3%＊＊＊ <0.0001
irregular visits to a medical institution 39.7% 26.9% 15.1%＊＊＊ 0.0152
none 34.5%＊ 11.8% 5.7%＊＊＊ 0.0001
Prehospital treatments (%)
oral corticosteroid 0%＊ 24.7% 22.6%＊＊＊ 0.0002
ICS 25.9%＊ 60.2% 77.4%＊＊＊ <0.0001
SABA monotherapy as needed 24.1% 19.4% 3.8%＊＊＊ 0.0105
no treatment 50.0%＊ 19.4% 17.0%＊＊＊ <0.0001
Days of hospitalization (days) 12.2 ± 8.4 16.1 ± 15.9 19.2 ± 13.6＊＊＊ 0.0084
＊P < 0.05; 15-34 years old vs. 35-64 years old.
＊＊P < 0.05; 35-64 years old vs. more than 65 years old.
＊＊＊P < 0.05; more than 65 years old vs. 15-34 years old.
herence.27,28 Continuous ICS use is associated with a
decreased numbers of emergency department visits29
and asthma related deaths.2,30 Treatment adherence
in the young age group was poor. However, 31% of pa-
tients in the young age group showed intermittent
type asthma, which does not always require continu-
ous treatment. Prehospital severity was classified on
the basis of GINA guidelines and subjective symp-
toms and treatments. Patients with intermittent type
asthma are not treated by continuous ICS use. We
previously examined patients with intermittent
asthma diagnosed on the basis of subjective symp-
toms. The percentage of patients classified into the
mild asthma group by all of the results of the three
tests (FEV1 [% predicted], airway hyperresponsive-
ness to histamine dihydrochloride, and exhaled nitric
oxide level) in patients with young adult asthma was
only 20.6%.31 We showed that asthma severity classi-
fied on the basis of subjective symptoms may be un-
derestimated in young adults. The difference in treat-
ment adherence and asthma severity among the
groups may be due to this underestimation. SABA
monotherapy is related to rebound airway hyperre-
sponsiveness,1 worsening of asthma,32 and increased
risk of asthma related death.33 In the young age
group, we consider that the strategies that remain to
be carried out in asthma management are to decrease
the numbers of patients without treatment and with
Background of Severe Asthma Exacerbation
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irregular visits to a medical institution, and to high-
light the necessity of long-term management with
medicines. The middle age group had high rates of
aspirin-intolerant asthma. Furthermore, the middle
age group had high rates of severe persistent asthma.
Many studies have shown that aspirin intolerance is a
risk factor for severe asthma.34 In the middle age
group, we consider that the problems remaining in
asthma treatments are the correct management of
risk factors for severe asthma including aspirin-
intolerant asthma. It is necessary for us to identify pa-
tients with aspirin-intolerant asthma. The advanced
age group had high rates of hypertensionheart dis-
ease, diabetes mellitus, and COPD. In patients with
acute asthma brought to the emergency department,
Tsai et al. reported that the number of patients with
hypertension or diabetes or COPD was significantly
higher among more than 55-year-old patients among
than among 18-54.9-year-old patients.35 The advanced
age group showed good treatment adherence, but
had high rates of severe persistent asthma. It was re-
ported that elderly patients do not adhere to medica-
tion guidelines.36 Elderly patients are not used to in-
haled medications, and it is difficult for them to cor-
rectly use inhaled medications. It is necessary for
doctors not only to prescribe medications, but also to
confirm the correct use of inhaled medications.
Moreover, elderly patients with asthma have various
complications, and a high percentage of them suc-
cumbed to asthma related deaths.
This study has limitations that should be consid-
ered when interpreting the findings. There were
many patients who did not visit our hospital before
admission. Therefore, we were unable to evaluate
their pulmonary function and bronchial hyperrespon-
siveness before admission. We determined prehospi-
tal asthma severity on the basis of only subjective
symptoms, because no pulmonary function tests were
performed. Moreover, Japanese people are a ho-
mogenous race. Therefore, racial differences that are
generally considered to be aggravating factors are
not considered. However, there are individual differ-
ences in socioeconomic background. In this study,
we were unable to clarify the patient’s socioeconomic
background. A prospective large-scale clinical trial
considering these limitations is essential in the fu-
ture.
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